Basic Information
| LncRNA/CircRNA Name | RP11-19E11.1 |
| Synonyms | NA |
| Region | GRCh38_2:118833700-118835110 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | PAC-1,Enzastaurin,YM201636 | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | RNA-seq, Western blot, qRT-PCR |
| Sample | cancer cells MDA-MB-231, Hs578T, MDA-MB-157, MDA-MB-468, MCF7, SkBr3, and BT474 |
| Expression Pattern | up-regulated |
| Function Description | lncRNA RP11-19E11.1 knock-down induces cell cycle arrest and apoptosis.lncRNA RP11-19E11.1 is a E2F1 target gene.LncRNA RP11-19E11.1 expression has predictive value for drug sensitivity in BL cell lines. |
| Pubmed ID | 31934613 |
| Year | 2020 |
| Title | LncRNA RP11-19E11 Is an E2F1 Target Required for Proliferation and Survival of Basal Breast Cancer |
External Links
| Links for RP11-19E11.1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |